Pharmaceutical and Biotechnology Companies Segment to Lead Glycomics Market During 2022-2028

According to our latest study on "Glycomics Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Product, Application, and End User," the market is expected to grow from US$ 1,340.80 million in 2021 to US$ 3,223.30 million by 2028; it is estimated to grow at a CAGR of 13.4% from 2022 to 2028. The report highlights the key factors and trends impacting the market and focuses on prominent players and their strategies.

Glycans are responsible for much of the structural variation in biologic systems, and their representation on cell surfaces is commonly called the "glycome." Glycomics is an emerging field that aims to focus on the structure and function of glycans in a cell, tissue, or organism. Glycans are chain-like structures of carbohydrates that are free or conjugated to macromolecules such as lipids or proteins. They contribute to a diverse selection of biological processes such as protein folding, cell signaling, and immune recognition. These are implicated in several diseases such as oncological, autoimmune, and others.

As scientists have concentrated their efforts in the glycomics field, they have started to learn important details about the functions of glycans and glycosylation in the body, including cellular communication and what these factors might reveal about disease development and diagnostics. The largest and fastest-growing application category is drug discovery and development, mostly due to the rise in R&D by pharmaceutical and biotechnology firms and the expansion of drug discovery research activities in university research institutions. For instance, in April 2020, to commercialize a cutting-edge cancer detection tool, researchers from the Institute for Glycomics and the University of Adelaide signed an exclusive licensing agreement with Sienna Cancer Diagnostics Ltd. These researchers have created a special protein called SubB2M, which attaches exclusively to a sugar molecule, only found in cancer cells. This protein might revolutionize the detection of cancer. In addition, in January 2022, The National Health and Medical Research Council (NHMRC) gave researchers from the Institute of Glycomics grants totaling more than US$ 1.1 billion to help them create new medicines to treat multidrug-resistant gonorrhea infections.

Thus, these advancements show that glycomics has the potential to provide rapid and accurate diagnostics methods that transcend diverse clinical indications and complex conditions. Therefore, the use in drug development for diseases across the world is a key factor driving the glycomics market.

Based on end user, the glycomics market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and contract research organizations. The pharmaceutical and biotechnology companies' segment is likely to hold the largest share of the market in 2021, and the same segment is expected to register the highest CAGR from 2022 to 2028. The rise in pharmaceutical and biotechnological products has resulted in massive market consolidations between biotechnology and pharmaceutical companies for enhanced and better treatment options. Investments made by companies have grown the market's pharmaceutical & biotechnology companies' segment. For instance, in July 2018, Agilent acquired ProZyme, Inc.-a leading provider of glycobiology products and bioanalytical proteins-to expand its product line into glycome products. ProZyme, Inc. is a leading developer and manufacturer of glycan reagents, kits, and standards, which are required for efficient sample prep to analyze free glycans. Thus, such inorganic strategies followed by companies for better utilization of opportunities to cater to customers and the rise in the need for novel treatment solutions for a broad range of health disorders are expected to boost the growth of this segment during the forecast period.

Impact of COVID-19 Pandemic on Glycomics Market

The COVID-19 pandemic heavily impacted the global market in all sectors as it tested the resilience of economies and placed immense pressure on governments to take restrictive measures to prevent the spread of the infection. During the lockdown periods, the healthcare industry encountered unprecedented challenges. Manufacturing units were closed, affecting the production of medical devices and other equipment. Supply chains of medical products were disrupted, resulting in an increase in warehouse inventory of manufactured products. In addition, the pandemic altered economic conditions and social behaviors in various countries. Containment measures enforced by governments changed the healthcare service delivery pattern worldwide. According to the Department of Emergency Medicine, in many countries across North America, emergency department (ED) visits decreased by ~40% in 2020. Moreover, outpatient appointments and elective treatments were postponed or replaced by telemedicine practices.

However, the increasing presence of drug companies and research institutions to aid in drug discovery and development related to the SARS-CoV-2 virus is boosting the glycomics market in Europe. Glycomics played an important role in the development of therapeutics and profiling the virus samples, as spike protein is the key antigen in the development of COVID-19 vaccines using glycomics. Therefore, various glycomics services provided by companies to profile the COVID-19 samples fueled the market growth during the COVID-19 pandemic. Furthermore, various collaborations between companies for vital research and development are boosting the market growth. For instance, QA-Bio Inc and Ludger Ltd. partnered to provide glycoanalytical services for SARS-CoV-2 samples. These service providers have around 20 years of experience analyzing glycosylation and are well regarded in the glycobiology community. Thus, the factors mentioned above led to the growth of the glycomics market during the COVID-19 pandemic.

Merck KGaA; Agilent Technologies, Inc.; New England Biolabs; Thermo Fisher Scientific Inc.; Waters Corporation; Asparia Glycomics; Bruker Corporation; Takara Bio Inc.; S-BIO; and Shimadzu Corporation are among the key players operating in the glycomics market.

The report segments the glycomics market as follows:

The glycomics market is segmented based on product, application, end user, and geography. Based on product, the market is segmented into enzymes, instruments, kits, and reagents. In terms of application, the glycomics market is segmented into drug discovery and development, diagnostics, immunology, cancer, and others. Based on end user, the market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and contract research organizations. Geographically, the glycomics market has been segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), APAC (China, India, Japan, Australia, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com